RGLS Regulus Therapeutics Inc.

1.04
-0.13  -11%
Previous Close 1.17
Open 1.16
Price To Book -103.67
Market Cap 21,790,048
Shares 21,018,663
Volume 233,735
Short Ratio
Av. Daily Volume 336,443
Stock charts supplied by TradingView

NewsSee all news

  1. Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326

    LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced

  2. Regulus Therapeutics to Present at the Stifel Healthcare Conference

    LA JOLLA, Calif., Nov. 18, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced

  3. Regulus Therapeutics Reports Third Quarter 2019 Financial Results and Recent Updates

    LA JOLLA, Calif., Nov. 12, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the

  4. Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD

    LA JOLLA, Calif., Sept. 12, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced

  5. Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference

    LA JOLLA, Calif., Sept. 3, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 enrollment has been paused due to financial conditions - noted July 5, 2018.
RG-012 - HERA
Alport Syndrome
Phase 1 clinical hold has been lifted - noted December 16, 2019. Trial to be re-initiated 1Q 2020.
RGLS4326
Autosomal dominant polycystic kidney disease (ADPKD)

Latest News

  1. Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326

    LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced

  2. Regulus Therapeutics to Present at the Stifel Healthcare Conference

    LA JOLLA, Calif., Nov. 18, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced

  3. Regulus Therapeutics Reports Third Quarter 2019 Financial Results and Recent Updates

    LA JOLLA, Calif., Nov. 12, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the

  4. Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD

    LA JOLLA, Calif., Sept. 12, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced

  5. Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference

    LA JOLLA, Calif., Sept. 3, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced

  6. Regulus Therapeutics to Present at the Wells Fargo Healthcare Conference

    LA JOLLA, Calif., Aug. 29, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced